Posted by Michael Wonder on 30 Sep 2021
DiaMedica Therapeutics announces fast track designation granted to DM199 for the treatment of acute ischaemic stroke
30 September 2021 - DiaMedica Therapeutics today announced that the U.S. FDA has granted fast track designation to the Company’s lead candidate DM199 for the treatment of acute ischaemic stroke where tissue plasminogen activator and/or mechanical thrombectomy are not indicated or medically appropriate.
DM199 is a recombinant form of human tissue kallikrein-1.
